Tests TNG462 in adults with advanced solid tumors lacking MTAP
Tests the pill TNG462, alone or with pembrolizumab, in adults with advanced MTAP-deleted solid tumors.
Key facts
- Who runs it
- Tango Therapeutics, Inc.
- Where
- Boston, Chicago, Detroit, Fairfax, Grand Junction, Houston, Lake Mary, Miami, Nashville, New York, Palo Alto, Salt Lake City, Urbana, and Zion, United StatesSee the 15 sitesAlso in 2 other countries, 11 sites
- Trial code
- Registry title
- Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 225 people, planned
- Started
- 26 May 2023
- Expected to end
- Jun 2028
- Type of study
- Interventional, 7 groups
- Treatments tested
- TNG462
- Pembrolizumab
- Record updated
- 8 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an advanced or metastatic solid tumor that has an MTAP deletion, to test the oral drug TNG462.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Locally advanced, metastatic or unresectable solid tumor, confirmed by tissue or cell tests.
- Earlier treatment
- Prior standard therapy, as available.
- Biomarker or test result
- A documented deletion of both copies of the MTAP gene in the tumor (found by next-generation sequencing), or no MTAP protein in the tumor (found by IHC).
Main reasons for not taking part
- Allergy or intolerance to TNG462 or its ingredients, or to pembrolizumab in the combination arms
- Active infection that needs treatment with medicines that act on the whole body
- Brain or spinal cord metastases with worsening neurological symptoms
- Active liver disease, or clinically relevant heart or blood vessel disease
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Age: ≥18 years-of-age at the time of signature of the main study ICF
- Performance status: ECOG Performance Score of 0 to 1
- Confirmed histologic or cytologic diagnosis of a locally advanced, metastatic, and/or unresectable solid tumor
- Prior standard therapy, as available
- Documented bi-allelic (homozygous) deletion of MTAP in a tumor detected by next- generation sequencing or absence of MTAP protein in a tumor detected by IHC
- Adequate organ function/reserve per local labs
- Adequate liver function per local labs
- Adequate renal function per local labs
- Negative serum pregnancy test result at screening
- Written informed consent must be obtained according to local guidelines
Who cannot take part
- Currently participating in or has planned participation in a study of another investigational agent or device
- Active prior or concurrent malignancy
- Known allergies, hypersensitivity, or intolerance to TNG462, or its excipients or to pembrolizumab in the combination treatment arms
- Uncontrolled intercurrent illness that will limit compliance with the study requirements
- Active infection requiring systemic therapy
- Impairment of GI function or disease that may significantly alter the absorption of oral TNG462
- Current active liver disease from any cause
- Clinically relevant cardiovascular disease
- Known to be HIV positive, unless all of the following criteria are met:; CD4+ count ≥300/μL; Undetectable viral load; Receiving highly active antiretroviral therapy
- Patient is unwilling or unable to comply with the scheduled visits, drug administration plan, laboratory tests, biopsy, or other study procedures and study restrictions
- Patient has a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, may affect the safety of the patient or impair the assessment of study results
- Central nervous system metastases associated with progressive neurological symptoms
- A female patient who is pregnant or lactating
Where in United States
Also in 2 other countries, 11 sites
- Dana-Farber Cancer InstituteBoston, United StatesContact: Candace Haddox, MD (principal investigator)Taking people
- Massachusetts General HospitalBoston, United StatesContact: Ibiayi Dagogo-Jack, MD (principal investigator)Taking people
- University Chicago MedicineChicago, United StatesContact: Hedy Kindler, MD (principal investigator)Taking people
- Henry Ford Cancer CenterDetroit, United StatesContact: Amy Weise, DO (principal investigator)Taking people
- NEXT Oncology- VirginiaFairfax, United StatesContact: Alexander Spira, MD, PhD (principal investigator)Taking people
- Grand Valley OncologyGrand Junction, United StatesContact: Jonathan King, MD (principal investigator)Taking people
- The University of Texas MD Anderson Cancer CenterHouston, United StatesContact: Jordi Rodon Ahnert, MD (principal investigator)Taking people
- Florida Cancer Specialists & Research InstituteLake Mary, United StatesContact: Maxim Pimpkin, MDNo longer taking part
- Sylvester Comprehensive Cancer Center*Miami, United StatesContact: Jose Lutzky, MD (principal investigator)Taking people
- Sarah Cannon - Tennessee OncologyNashville, United StatesContact: David Spigel, MD (principal investigator)Taking people
- New York University Langone HealthNew York, United StatesContact: Salman Punekar, MD (principal investigator)Taking people
- Stanford UniversityPalo Alto, United StatesContact: Christopher Chen (principal investigator)Taking people
- Huntsman Cancer Institute/University of UtahSalt Lake City, United StatesContact: Vaia Florou, MD, MS (principal investigator)Taking people
- Carle Cancer CenterUrbana, United StatesContact: Tammay Sahai, MD (principal investigator)Taking people
- Midwestern Regional Medical Center, City of Hope ChicagoZion, United StatesContact: Evan Pisick, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
The 7 groups in the trial
- Dose EscalationTreatment being tested
Participants with MTAP-deleted solid tumors (excluding primary CNS) will receive escalating doses of TNG462 single agent and in combination with pembrolizumab to estimate the MTD
Treatment: TNG462 and Pembrolizumab
- Dose Expansion in NSCLCTreatment being tested
Participants with MTAP-deleted NSCLC (squamous and non squamous) will receive TNG462 at the identified RP2D(s)
Treatment: TNG462
- Dose Expansion in MesotheliomaTreatment being tested
Participants with MTAP-deleted mesothelioma will receive TNG462 at the identified RP2D(s)
Treatment: TNG462
- Dose Expansion in Pancreatic Ductal AdenocarcinomaTreatment being tested
Participants with MTAP-deleted pancreatic ductal adenocarcinoma will receive TNG462 at the identified RP2D(s)
Treatment: TNG462
- Dose Expansion in SarcomaTreatment being tested
Participants with MTAP-deleted sarcoma (soft tissue or bone) will receive TNG462 at the identified RP2D(s)
Treatment: TNG462
- Dose Expansion in Solid TumorsTreatment being tested
Participants with other MTAP-deleted solid tumors will receive TNG462 at the identified RP2D(s)
Treatment: TNG462
- Dose Expansion in NSCLC in Combination with PembrolizumabTreatment being tested
Participants NSCLC (squamous and non squamous) MTAP-deleted solid tumors will receive TNG462 at the identified RP2D(s)
Treatment: TNG462 and Pembrolizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
- Plain-language title
- Tests TNG462 in adults with advanced solid tumors lacking MTAPGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 8 September 2026